ARCHIMED Acquires and Merges Symbio and Proinnovera to Form Symbio Proinnovera
November 17, 2023
Global private equity healthcare specialist ARCHIMED acquired US-based Symbio and Germany-based Proinnovera in an all-equity deal and simultaneously merged them. The resulting Symbio Proinnovera is a dermatology-focused contract research organization (CRO) offering outsourced dermatological therapy formulation and clinical trial testing across the full development lifecycle.
- Buyers
- ARCHIMED
- Targets
- Symbio, Proinnovera
- Industry
- Healthcare Services
- Location
- Germany
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
ARCHIMED Acquires Groupe Laboratoire Rivadis
September 8, 2025
Consumer Products
ARCHIMED, a healthcare-focused private equity firm, has acquired Groupe Laboratoire Rivadis, a French developer and manufacturer of dermo-cosmetics and hygiene products (brands include Rivadouce, Milton and Auriège). The seller, majority shareholder Christian Lainé, is reinvesting a meaningful portion of proceeds; ARCHIMED plans to support Rivadis' growth and strengthen its position in the consumer health / dermo-cosmetics market.
-
ARCHIMED Acquires BioVendor Group
March 11, 2025
Medical Devices
ARCHIMED, a Europe-focused private equity firm specializing in healthcare, has acquired BioVendor Group, a Brno-headquartered developer and manufacturer of in‑vitro diagnostics and immunoassays. ARCHIMED will partner with existing management to accelerate internationalization, product innovation and commercial expansion as part of its MED III fund's diagnostics investment strategy.
-
ARCHIMED Acquires WiQo S.p.A.
March 9, 2023
Medical Devices
ARCHIMED, a Europe-based healthcare private equity firm, has acquired WiQo, an Italian developer and manufacturer of the PRX‑T33 topical biostimulator used in aesthetic medicine. Founders (Dr. Rossana Castellana and family) retained a 25% stake and Castellana will stay on to lead R&D; the deal was financed with debt provided by Banco BPM and Crédit Agricole Italia and is the fourth investment from ARCHIMED's MED III fund.
-
ARCHIMED (via MED Platform I) Acquires Majority Stake in SUANFARMA
November 18, 2021
Pharmaceuticals
Transatlantic healthcare-focused private equity firm ARCHIMED, through its MED Platform I (MPI) fund, has acquired a majority stake in Madrid-based SUANFARMA, a manufacturer and distributor of active pharmaceutical ingredients (APIs) and nutraceutical ingredients. Ares Management provided debt financing for the transaction; SUANFARMA founder Héctor Ara and members of management rolled a material minority stake into the business and remain significant shareholders.
-
ARCHIMED Acquires Majority Stake in Cube (Cube Biotech)
November 3, 2021
Biotechnology
Transatlantic healthcare private equity firm ARCHIMED has purchased a majority stake in Monheim, Germany-based Cube (Cube Biotech), a specialist provider of high-purity, stable membrane proteins for drug discovery. ARCHIMED will support Cube's US market expansion and broaden its product and service offering organically and via acquisitions while Cube's founding management remain significant shareholders and continue to lead the business.
-
ARCHIMED Acquires Majority Stake in Germany's Zyto Group
January 12, 2021
Medical Devices
ARCHIMED, through its MED II fund, has acquired a majority stake in the Zyto group — a German developer, manufacturer and distributor of advanced cancer diagnostics, including Zytomed, ZytoVision and 42 Life Sciences. The deal will keep founders and management as significant minority shareholders and is intended to accelerate product innovation, regulatory capabilities and international expansion of the group's precision oncology diagnostics.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.